Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Johnson & Johnson: Pharma Growth Strategy' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Johnson & Johnson: Pharma Growth Strategy How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues? |
July 2009 | £245 | 99 % |
|
Johnson & Johnson PharmaVitae Profile |
July 2008 | £3010 | 50 % |
|
Watson Pharmavitae Generics Profile |
September 2007 | £2005 | 36 % |
|
Johnson & Johnson Inc: OTC Healthcare |
January 2007 | £195 | 35 % |
|
Product Lifecycle Management, 2006 |
May 2006 | £1499 | 32.5 % |
|
Best Practices in Designing Effective Brand Teams Brand Governance and Brand Team Management |
December 2007 | £2145 | 30 % |
|
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £1955 | 29.05 % |
|
Mergers and Aquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £995 | 29.05 % |
|
Eisai: Pipeline, Products, Performance, Potential |
November 2009 | £595 | 27.5 % |
|
Johnson & Johnson Prospects to 2010 |
June 2007 | £595 | 27 % |
|
Johnson & Johnson: PharmaVitae Profile Healthcare |
July 2009 | £5700 | 26.95 % |
|
Eisai Pipeline - Products - Performance - Potential |
June 2008 | £595 | 25.5 % |
|
Mentor Medical Device Company Intelligence Report |
August 2009 | £295 | 24 % |
|
China Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 Analysis and Forecasts to 2015 |
April 2009 | £1590 | 23 % |
|
Key Trends in Offshoring Pharmaceutical R&D Company strategies, emerging markets and impact on ROI |
March 2009 | £2025 | 22.05 % |
|
Tanabe Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 20.65 % |
|
Shionogi: Pipeline - Products - Performance - Potential |
March 2008 | £595 | 19.6 % |
|
Amgen Prospects to 2010 |
February 2009 | £595 | 18.55 % |
|
Shire: Pipeline • Products • Performance • Potential |
December 2008 | £595 | 16.1 % |
|
The Top 35 Central Nervous System Drug Delivery Technology Companies Worldwide |
May 2005 | £250 | 15.5 % |
|
The Top 50 Neurodevice Companies Worldwide |
June 2009 | £305 | 15 % |
|
Lundbeck Pharmaceutical Company Intelligence Report Performance, Products, Pipeline and Potential |
March 2009 | £595 | 14.7 % |
|
Monoclonal Antibodies Report Part II Companies - Holding Mabs In Portfolio Promises Protection Against The Looming 2011-12 Patent Cliff |
September 2007 | £3800 | 14.7 % |
|
AMD Market Outlook to 2012 |
March 2007 | £1299 | 14.35 % |
|
U.S. and Worldwide Monoclonal Antibody Medicine Current Status and Future Trends |
August 2008 | £700 | 13.3 % |
|
Forecast Insight: HIV |
June 2009 | £15200 | 13.3 % |
|
M&A trends in Pharma |
October 2008 | £6000 | 13.3 % |
|
Abbott Laboratories: PharmaVitae Profile Healthcare |
September 2009 | £5700 | 12.95 % |
|
World Gastrointestinal Disorders Market 2006-2011; The |
January 2006 | £1799 | 12.6 % |
|
Lymphoma Drug Development Strategies at Work |
June 2009 | £1700 | 12.25 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1700 | 11.9 % |
|
Pfizer Market Outlook for a Global Leader, 2008-2013 |
August 2008 | £1499 | 11.9 % |
|
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands Healthcare |
March 2009 | £8000 | 11.55 % |
|
Gastrointestinal Disorders Market Intelligence to 2012 |
May 2007 | £1499 | 11.55 % |
|
Contract Pharma 2008-2023 |
August 2008 | £1499 | 10.85 % |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2140 | 10.85 % |
|
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 |
February 2007 | £1499 | 10.85 % |
|
Direct to Consumer (DTC) Advertising in Pharmaceuticals Current and Future Market Outlook, Regulatory Landscape and Case Studies |
December 2009 | £2230 | 10.5 % |
|
World Generics Market, 2008-2013 |
November 2008 | £1499 | 9.8 % |
|
World Gastrointestinal Disorders Market 2008-2023 |
October 2008 | £1499 | 9.8 % |
|
DePuy, Inc. Product Pipeline Analysis |
August 2008 | £475 | 9.8 % |
|
U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Products |
March 2006 | £1910 | 9.8 % |
|
Cardiac Marker Diagnostic Testing Markets |
May 2008 | £2165 | 9.8 % |
|
Stakeholder Opinions: Hormonal Contraceptives New directions in a competitive market |
November 2006 | £2005 | 9.8 % |
|
Biosimilars and Follow-On Biologics Report The Global Outlook 2009-2024 |
April 2009 | £1499 | 9.45 % |
|
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012 |
April 2007 | £1499 | 9.45 % |
|
Antiageing and Life Enhancement Pharmacotherapeutics |
January 2006 | £795 | 8.4 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £8000 | 7 % |
|
Generic League Market Analysis and Forecasts, 2007-2012, 2017 & 2022 |
February 2008 | £1999 | 6.65 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 6.3 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £6000 | 6.3 % |
|
Pipeline Insight: Bipolar Disorder New treatments for bipolar depression set to drive near-term growth |
September 2006 | £6495 | 5.6 % |
|
Laparoscopic Devices Market Research Report Worldwide |
June 2009 | £1270 | 5.25 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2009 / 2010 |
June 2009 | £270 | 5.25 % |
|
Online Pharmaceutical Industry, 2006-2011, The |
July 2006 | £1499 | 5.25 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2165 | 5.25 % |
|
Blood Glucose Testing and Diabetes Management |
April 2009 | £2165 | 5.25 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £270 | 4.9 % |
|
Gastrointestinal Endoscopy Systems and Instruments A Market Strategy Report |
March 2006 | £950 | 4.55 % |
|
Point of Care Diagnostics: Players, Products & Future Market Prospects |
November 2009 | £995 | 3.15 % |
